FDA Peptide Reclassification 2026: What It Means for Providers FDA takes first step in possible reversal of ban on some peptides The Washington Post FDA to weigh easing limits on unproven peptides Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives In 2023, the FDA deemed 19 peptides too unsafe to be dispensed by compounding pharmacies. Now, under RFK Jr., the agency is poised to reverse itself despite the fact that few The Unregulated World of Peptides: A Legal Minefield for Providers Holt Law